Single variants can explain the association between coronary heart disease and haplotypes in the apolipoprotein(a) locus

Atherosclerosis

Volumn 212, Issue 1, 2010, Pages 193-196

  Shiffman, Dov ^a   Louie, Judy Z ^a   Rowland, Charles M ^a   Malloy, Mary J ^b   Kane, John P ^b   Devlin, James J ^a  

^a CELERA   (United States)

^b UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

CHD; Genetics; LPA

Indexed keywords

APOLIPOPROTEIN A;

ALLELE; ARTICLE; CONFIDENCE INTERVAL; CONTROLLED STUDY; GENE LOCUS; GENETIC ASSOCIATION; HAPLOTYPE; HUMAN; ISCHEMIC HEART DISEASE; PRIORITY JOURNAL; SINGLE NUCLEOTIDE POLYMORPHISM;

APOPROTEIN(A); CALIFORNIA; CASE-CONTROL STUDIES; CORONARY DISEASE; GENE FREQUENCY; GENETIC PREDISPOSITION TO DISEASE; HAPLOTYPES; HUMANS; LOGISTIC MODELS; ODDS RATIO; PHENOTYPE; POLYMORPHISM, SINGLE NUCLEOTIDE; RISK ASSESSMENT; RISK FACTORS;

EID: 77956227262     PISSN: 00219150     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.atherosclerosis.2010.05.009     Document Type: Article

References (22)

1. Bennet A., Di Angelantonio E., Erqou S., et al. Lipoprotein(a) levels and risk of future coronary heart disease: large-scale prospective data. Arch Intern Med 2008, 168:598-608.
2. Kamstrup P.R., Benn M., Tybaerg-Hansen A., Nordestgaard B.G. Extreme lipoprotein(a) levels and risk of myocardial infarction in the general population: the Copenhagen City Heart Study. Circulation 2008, 117:176-184.
3. Erqou S., Kaptoge S., Perry P.L., et al. Lipoprotein(a) concentration and the risk of coronary heart disease, stroke, and nonvascular mortality. JAMA 2009, 302:412-423.
4. Valentine R.J., Grayburn P.A., Vega G.L., Grundy S.M. Lp(a) lipoprotein is an independent, discriminating risk factor for premature peripheral atherosclerosis among white men. Arch Intern Med 1994, 154:801-806.
5. Cheng S.W., Ting A.C., Wong J. Lipoprotein (a) and its relationship to risk factors and severity of atherosclerotic peripheral vascular disease. Eur J Vasc Endovasc Surg 1997, 14:17-23.
6. Molgaard J., Klausen I.C., Lassvik C., et al. Significant association between low-molecular-weight apolipoprotein(a) isoforms and intermittent claudication. Arterioscler Thromb 1992, 12:895-901.
7. Catalano M., Cortelazzo A., Yilmaz Y., et al. The LPA gene C93T polymorphism influences plasma lipoprotein(a) levels and is independently associated with susceptibility to peripheral arterial disease. Clin Chim Acta 2008, 387:109-112.
8. Boerwinkle E., Leffert C.C., Lin J., et al. Apolipoprotein(a) gene accounts for greater than 90% of the variation in plasma lipoprotein(a) concentrations. J Clin Invest 1992, 90:52-60.
9. Kraft H.G., Köchl S., Menzel H.J., Sandholzer C., Utermann G. The apolipoprotein (a) gene: a transcribed hypervariable locus controlling plasma lipoprotein (a) concentration. Hum Genet 1992, 90:220-230.
10. Trégouët D.A., König I.R., Erdmann J., et al. Genome-wide haplotype association study identifies the SLC22A3-LPAL2-LPA gene cluster as a risk locus for coronary artery disease. Nat Genet 2009, 41:283-285.
11. Luke M.M., Kane J.P., Liu D.M., et al. A polymorphism in the protease-like domain of apolipoprotein(a) is associated with severe coronary artery disease. Arterioscler Thromb Vasc Biol 2007, 27:2030-2036.
12. Shiffman D., Kane J.P., Louie J.Z., et al. Analysis of 17,576 potentially functional SNPs in three case-control studies of myocardial infarction. PLoS ONE 2008, 3:e2895.
13. Shiffman D., O'Meara E.S., Bare L.A., et al. Association of gene variants with incident myocardial infarction in the Cardiovascular Health Study. Arterioscler Thromb Vasc Biol 2008, 28:173-179.
14. Chasman D.I., Shiffman D., Zee R.Y., et al. Polymorphism in the apolipoprotein(a) gene, plasma lipoprotein(a), cardiovascular disease, and low-dose aspirin therapy. Atherosclerosis 2009, 203:3716.
15. Clarke R., Peden J.F., Hopewell J.C., et al. Genetic variants associated with Lp(a) lipoprotein level and coronary disease. N Engl J Med 2009, 361:2518-2528.
16. Shiffman D., Chasman D.I., Ballantyne C.M., et al. Coronary heart disease risk, aspirin use, and apolipoprotein(a) 4399Met allele in the Atherosclerosis Risk in Communities (ARIC) study. Thromb Haemost 2009, 102:179-180.
17. Schaid D.J., Rowland C.M., Tines D.E., Jacobsen R.M., Poland G.A. Score tests for association between traits and haplotypes when linkage phase is ambiguous. Am J Hum Genet 2002, 70:425-434.
18. Lake S., Lyon H., Silverman E., et al. Estimation and tests of haplotype-environment interaction when linkage phase is ambiguous. Hum Hered 2003, 44:56-65.
19. Gavish D., Azrolan N., Breslow J.L. Plasma Lp(a) concentration is inversely correlated with the ratio of Kringle IV/Kringle V encoding domains in the apo(a) gene. J Clin Invest 1989, 84:2021-2027.
20. Peros E., Geroldi D., D'Angelo A., et al. Apolipoprotein(a) phenotypes are reliable biomarkers for familial aggregation of coronary heart disease. Int J Mol Med 2004, 13:243-247.
21. McLean J.W., Tomlinson J.E., Kuang W.J., et al. cDNA sequence of human apolipoprotein(a) is homologous to plasminogen. Nature 1987, 330:132-137.
22. Marcovina S.M., Koschinsky M.L. Evaluation of lipoprotein(a) as a prothrombotic factor: progress from bench to bedside. Curr Opin Lipidol 2003, 14:361-366.